Lumiracoxib

Lumiracoxib Uses, Dosage, Side Effects, Food Interaction and all others data.

Lumiracoxib is a COX-2 selective non-steroidal anti-inflammatory drug (NSAID). On August 11, 2007, Australia's Therapeutic Goods Administration (TGA, the Australian equivalent of the FDA) cancelled the registration of lumiracoxib in Australia due to concerns that it may cause liver failure. New Zealand and Canada have also followed suit in recalling the drug.

Lumiracoxib has a different structure from the standard COX-2 inhibitors (e.g. celecoxib). It more closely resembles the structure of diclofenac (one chlorine substituted by fluorine, the phenylacetic acid has another methyl group in meta position), making it a member of the arylalkanoic acid family of NSAIDs. It binds to a different site on the COX-2 receptor than the standard COX-2 inhibitors. It displays extremely high COX-2 selectivity.

Table Of contents

• Lumiracoxib
• Uses
• Dosage
• Side Effect
• Precautions
• Interactions
• Uses during Pregnancy
• Uses during Breastfeeding
• Accute Overdose
• Food Interaction
• Half Life
• Volume of Distribution
• Clearance
• Interaction With other Medicine
• Contradiction
• Storage

Trade Name	Lumiracoxib
Generic	Lumiracoxib
Lumiracoxib Other Names	Lumiracoxib, Lumiracoxibum
Type
Formula	C15H13ClFNO2
Weight	Average: 293.721 Monoisotopic: 293.061884577
Protein binding	Highly bound to plasma proteins (>= 98%).
Groups	Approved, Investigational
Therapeutic Class
Manufacturer
Available Country
Last Updated:	September 19, 2023 at 7:00 am

Uses

For the acute and chronic treatment of the signs and symptoms of osteoarthritis of the knee in adults.

How Lumiracoxib works

The mechanism of action of lumiracoxib is due to inhibition of prostaglandin synthesis via inhibition of cyclooygenase-2 (COX-2). Lumiracoxib does not inhibit COX-1 at therapeutic concentrations.

Toxicity

Single oral doses in mice and rats resulted in mortality and/or moribundity at doses of 600 mg/kg and 500 mg/kg, respectively. Single intraperitoneal doses in mice and rats results in mortality/moribundity at 750 mg/kg and 1000 mg/kg, respectively. The maximum non-lethal single oral and intraperitoneal dose in mouse was 300 mg/kg and 250 mg/kg, respectively. In the rat it was 150 mg/kg and 250 mg/kg, respectively.

Food Interaction

• Take with or without food. The absorption is unaffected by food.

Elimination Route

Rapidly absorbed following oral administration, with an absolute oral bioavailablity of 74%.

Half Life

Terminal half-life is approximately 4 hours.

Innovators Monograph

You find simplified version here Lumiracoxib